Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
Cybin Inc. (CYBN) filed a Form D announcing the completion of a Rule 506(b) private placement. The Ontario-based psychedelic therapeutics company sold $50 million in a mix of debt securities, warrants/options, and underlying shares. The first sale occurred on 30 June 2025 and the offering will not extend beyond one year. All of the targeted amount has been placed, leaving $0 remaining.
Key terms
- Total offering size: $50,000,000
- Securities type: Debt plus equity-linked instruments
- Number of investors: 1 (accredited status not disclosed)
- Sales commissions: $2,670,000 (Joseph Gunnar & Co., LLC)
- Finder’s fees: $0
- Proceeds earmarked for insiders: $0
The issuer declined to disclose revenue or asset size. The financing adds fresh capital without immediate payments to executives or directors and is not tied to a merger or acquisition. The exemption selected (Rule 506(b)) restricts general solicitation and requires sales only to accredited investors or up to 35 non-accredited sophisticated purchasers.